New Supply of CroFab™ Snakebite Antivenom Shipping This Week

Melville, NY – July 29, 2002 – Savage Laboratories®, a division of Altana Inc., announced today that the Food and Drug Administration has released 2,882 vials (1,441 cartons) of CroFab^TM; (Crotalidae Polyvalent Immune Fab -- Ovine) for shipment immediately. The vials will be shipped to wholesalers this week. This shipment follows 1,788 vials that were released July 17th. The shipments represent the second and third shipments this year. In March, Savage Laboratories announced that the outsourced process for the filling and freeze drying of CroFab^TM; was found to be out of specification, which resulted in a two-month delay in the release of CroFab^TM; to the market. The first shipment of CroFab^TM (3,628 vials) was not released until early June. Savage Laboratories anticipates the fourth shipment (2,718 vials) will ship by the middle of August.

CroFab^TM; is indicated for the management of patients with minimal or moderate North American crotalid envenomation. The term crotalid describes the Crotalidae family of venomous snakes, which includes rattlesnakes, copperheads and cottonmouths/water moccasins. CroFab^TM;, developed and manufactured by Protherics Inc., is one of two crotalid antivenoms available in the United States. Antivenin Crotalidae Polyvalent is produced by and marketed by Wyeth-Ayerst Laboratories, Inc.

About Savage Labs
Savage Laboratories® is a division of Altana, Inc., the U.S. subsidiary of ALTANA Pharma AG, a multi-national pharmaceutical company based in Konstanz, Germany. Currently the strategic focus of Savage Laboratories is emergency/critical care and women’s health care. More information is available at www.savagelabs.com.

CONTACT: Russell LaMontagne of Corinth Group Communications, for Savage Laboratories(R), 212/255-5340